Literature DB >> 8200995

Mineralocorticoids, hypertension, and cardiac fibrosis.

M Young1, M Fullerton, R Dilley, J Funder.   

Abstract

Uninephrectomized rats drinking 1% sodium chloride were given aldosterone (Aldo, 0.75 microgram/h, subcutaneous [s.c.] infusion), deoxycorticosterone (DOC, 20 mg/wk, s.c.), corticosterone (B, 2 mg/d, s.c.), or the antiglucocorticoid-antiprogestin RU486 (2 mg/d, s.c.) for 8 wk, and hemodynamic and tissue responses were compared with a non-steroid-treated control group. Aldo and DOC markedly increased systolic BP and caused considerable (40-50%) cardiac hypertrophy; B and RU486 caused neither hypertension nor cardiac hypertrophy. Measurements of ventricular cross-sectional areas showed hypertrophy due to an increase in mass of the left ventricle only. Cardiac hydroxyproline concentration was increased considerably by Aldo and DOC, to a lesser degree by RU486, and not by B. Aldo markedly elevated left ventricular interstitial collagen (2.5-fold vs control, P < 0.01 vs all groups); other steroid treatments also increased interstitial collagen over control (DOC x 1.8-, RU486 x 1.6-, B x 1.3-fold), with identical responses for right and left ventricles (r = 0.94). A different pattern of perivascular fibrosis was noted; DOC elevated perivascular collagen (2.1-fold vs control, P < 0.01 vs all other groups); RU486 raised levels 1.4-fold vs control, but neither Aldo nor B significantly affected perivascular collagen. These data are consistent with interstitial cardiac fibrosis reflecting type I (mineralocorticoid) receptor occupancy by administered Aldo or DOC, or by elevated endogenous B after type II (glucocorticoid) receptor blockade after RU486 administration; perivascular fibrosis may reflect a composite response after type I receptor agonist/type II glucocorticoid receptor antagonist occupancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200995      PMCID: PMC294488          DOI: 10.1172/JCI117269

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Glucocorticoid receptors mediate mineralocorticoid-like effects in cultured collecting duct cells.

Authors:  A Náray-Fejes-Tóth; G Fejes-Tóth
Journal:  Am J Physiol       Date:  1990-10

Review 2.  What is the role of the central nervous system in mineralocorticoid hypertension?

Authors:  E P Gómez Sánchez
Journal:  Am J Hypertens       Date:  1991-04       Impact factor: 2.689

Review 3.  On making multiple comparisons in clinical and experimental pharmacology and physiology.

Authors:  J Ludbrook
Journal:  Clin Exp Pharmacol Physiol       Date:  1991-06       Impact factor: 2.557

4.  Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor.

Authors:  C R Edwards; P M Stewart; D Burt; L Brett; M A McIntyre; W S Sutanto; E R de Kloet; C Monder
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

5.  Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney.

Authors:  W R Mercer; Z S Krozowski
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

6.  Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.

Authors:  J W Funder; P T Pearce; R Smith; A I Smith
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

7.  ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension.

Authors:  E P Gómez-Sánchez; M T Venkataraman; D Thwaites; C Fort
Journal:  Am J Physiol       Date:  1990-04

8.  Apparent mineralocorticoid excess, pseudohypoaldosteronism, and urinary electrolyte excretion: toward a redefinition of mineralocorticoid action.

Authors:  J W Funder; P T Pearce; K Myles; L P Roy
Journal:  FASEB J       Date:  1990-11       Impact factor: 5.191

9.  Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone.

Authors:  C Jonat; H J Rahmsdorf; K K Park; A C Cato; S Gebel; H Ponta; P Herrlich
Journal:  Cell       Date:  1990-09-21       Impact factor: 41.582

10.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12
View more
  74 in total

1.  CYP11B2 expression in HSCs and its effect on hepatic fibrogenesis.

Authors:  Xu Li; Ying Meng; Xi-Shan Yang; Ping-Sheng Wu; Shu-Mei Li; Wen-Yan Lai
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts.

Authors:  K Rombouts; A Wielant; K Hellemans; D Schuppan; A Geerts
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 3.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 4.  Aldosterone and vascular damage.

Authors:  D Duprez; M De Buyzere; E R Rietzschel; D L Clement
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

5.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 6.  Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome.

Authors:  Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2010-06-09       Impact factor: 2.801

Review 7.  The role of aldosterone in the metabolic syndrome.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

8.  Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Authors:  Richard J Auchus
Journal:  Endocrinology       Date:  2015-12-23       Impact factor: 4.736

Review 9.  Aldosterone in heart disease.

Authors:  Anastasia S Mihailidou
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

10.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.